Sign In
Buy IONS
$55.07
+0.580 (+1.06%)
At Close: Aug 04, 2026
Ionis to present at upcoming investor conferences
07:05am, Wednesday, 30'th Aug 2023
CARLSBAD, Calif. , Aug. 30, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences:
Ionis (IONS) Q2 Loss Narrows Y/Y, Sales Surpass Estimates
01:00pm, Thursday, 10'th Aug 2023
Ionis (IONS) Q2 loss narrows from the year-ago levels. Sales beat estimates.
Ionis Pharmaceuticals (IONS) Reports Q2 Results: What Key Metrics Have to Say (Revised)
11:31am, Thursday, 10'th Aug 2023
The headline numbers for Ionis Pharmaceuticals (IONS) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall St
Ionis Pharmaceuticals (IONS) Reports Q2 Earnings: What Key Metrics Have to Say
10:42am, Wednesday, 09'th Aug 2023
The headline numbers for Ionis Pharmaceuticals (IONS) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall St
Ionis Pharmaceuticals (IONS) Q2 Earnings and Revenues Surpass Estimates
09:58am, Wednesday, 09'th Aug 2023
Ionis Pharmaceuticals (IONS) came out with quarterly earnings of $0.60 per share, beating the Zacks Consensus Estimate of a loss of $0.94 per share. This compares to loss of $0.74 per share a year ago
Ionis to hold second quarter 2023 financial results webcast
07:05am, Wednesday, 26'th Jul 2023
Webcast scheduled for Wednesday, August 9 at 11:30 a.m. Eastern Time CARLSBAD, Calif.
Ionis (IONS) Posts Encouraging Data From Amyloidosis Drug Study
11:03am, Tuesday, 11'th Jul 2023
Ionis (IONS) reports positive 85-week phase III study data, supporting the benefits of eplontersen as a treatment for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).
Ionis to present at upcoming investor conference
07:05am, Wednesday, 05'th Jul 2023
CARLSBAD, Calif. , July 5, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in a fireside chat at TD Cowen's 2nd Annual RNA Therapeutics
Ionis (IONS) Posts Two-Year Upbeat Data From HAE Drug Study
01:39pm, Friday, 02'nd Jun 2023
Data from a mid-stage study shows that treatment with Ionis' (IONS) donidalorsen over a two-year period resulted in consistent and sustained protection from HAE attacks.
Ionis Pharmaceuticals (IONS) Up 19.3% Since Last Earnings Report: Can It Continue?
12:39pm, Friday, 02'nd Jun 2023
Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock?
Ionis to present at upcoming investor conferences
07:05am, Tuesday, 09'th May 2023
CARLSBAD, Calif. , May 9, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: RBC
Ionis (IONS) Q1 Earnings Surpass Estimates, Sales Match
10:41am, Thursday, 04'th May 2023
Ionis (IONS) reports a narrower-than-expected Q1 loss. Sales come in line with estimates.
Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Tops Revenue Estimates
09:55am, Wednesday, 03'rd May 2023
Ionis Pharmaceuticals (IONS) came out with a quarterly loss of $0.87 per share versus the Zacks Consensus Estimate of a loss of $1. This compares to loss of $0.46 per share a year ago.
Biotech/Drug Stocks' Q1 Earnings Due May 3: UTHR, PCRX & More
02:32pm, Tuesday, 02'nd May 2023
Let us take a look at what's in store for biotech/drug stocks UTHR, PCRX, CORT, AMRN and IONS, which are scheduled to report on May 3.
3 Biotech Stocks to Sell Before They're 6 Feet Under
02:37pm, Monday, 24'th Apr 2023
In a high-interest-rate environment, cash is king. All biotech companies will need to continue spending to finance their R&D.
